微信公众号
证券之星APP
| 报告期 | 净资产收益率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | -0.23% | 70.89% | 96.28% | 118/157 | 0.06% | 泽璟制药 | 44.02% | 行业排名> |
| 2025-12-31 | -6.18% | -43.72% | -167.1% | 113/157 | -4.46% | 泽璟制药 | 45.29% | 行业排名> |
| 2025-09-30 | 9.21% | 1687.93% | 298.06% | 26/157 | 1.31% | 兴齐眼药 | 38.62% | 行业排名> |
| 2025-06-30 | -4.65% | -247.01% | -488.61% | 129/157 | 0.3% | 兴齐眼药 | 32.91% | 行业排名> |
| 2025-03-31 | -0.79% | -51.92% | 81.63% | 121/157 | -0.34% | 翰宇药业 | 18.95% | 行业排名> |
| 2024-12-31 | -4.3% | 78.34% | -641.38% | 110/157 | -9.62% | 翰宇药业 | 11.39% | 行业排名> |
| 2024-09-30 | -0.58% | -256.76% | 56.72% | 116/157 | 4.28% | 百利天恒 | 181.27% | 行业排名> |
| 2024-06-30 | -1.34% | 87.67% | -157.69% | 121/157 | 2.69% | 百利天恒 | 186.1% | 行业排名> |
| 2024-03-31 | -0.52% | 40.23% | 97.38% | 119/157 | 2.35% | 百利天恒 | 186.89% | 行业排名> |
| 2023-12-31 | -19.85% | 37.48% | -5464.87% | 133/157 | -1% | 百利天恒 | 188.56% | 行业排名> |
| 2023-09-30 | 0.37% | 101.78% | 103.4% | 113/157 | 2.36% | 小方制药 | 41.8% | 行业排名> |
| 2023-06-30 | -10.87% | -1.3% | -1149.43% | 135/157 | 1.48% | 拓新药业 | 20.51% | 行业排名> |
| 2023-03-31 | -0.87% | 87.37% | 97.26% | 123/157 | 1.37% | 拓新药业 | 19.87% | 行业排名> |
| 2022-12-31 | -31.75% | 27.35% | -53.16% | 138/157 | 0.79% | 拓新药业 | 19.91% | 行业排名> |
| 2022-09-30 | -20.73% | -33.66% | -93.2% | 135/157 | 2.86% | 小方制药 | 55.57% | 行业排名> |
| 2022-06-30 | -10.73% | 23.63% | -55.73% | 139/157 | 2.21% | 福元医药 | 25.41% | 行业排名> |
| 2022-03-31 | -6.89% | -86.72% | 84.23% | 130/157 | 1.59% | 小方制药 | 34.81% | 行业排名> |
| 2021-12-31 | -43.7% | -97.47% | -181.75% | 139/157 | 0.84% | 退市金泰 | 10.74% | 行业排名> |
| 2021-09-30 | -15.51% | 15.89% | -10.39% | 126/157 | 4.46% | ST人福 | 6.82% | 行业排名> |
| 2021-06-30 | -14.05% | -48.52% | -280.76% | 136/157 | 2.99% | 小方制药 | 71.99% | 行业排名> |
| 2021-03-31 | -3.69% | 7.75% | 83.33% | 119/157 | 2.49% | 汇宇制药 | 39.25% | 行业排名> |
| 2020-12-31 | -22.13% | 82.93% | -20.01% | 130/157 | 3.8% | 汇宇制药 | 28.14% | 行业排名> |
| 2020-09-30 | -18.44% | -7192.31% | -94.93% | 112/157 | 3.13% | 哈三联 | 27.17% | 行业排名> |
| 2020-06-30 | -9.46% | -881.82% | -136.5% | 122/157 | 4.28% | 汇宇制药 | 55.94% | 行业排名> |
| 2020-03-31 | -4% | -278.57% | 96.92% | 105/157 | 2.23% | 中哲精化 | 45.32% | 行业排名> |
| 2019-12-31 | -129.68% | -1685.33% | -49976.92% | 132/157 | 2.57% | 汇宇制药 | 31.9% | 行业排名> |
| 2019-09-30 | 0.26% | -96.23% | -78.51% | 96/157 | 7.58% | 誉衡药业 | 35.56% | 行业排名> |
| 2019-06-30 | 1.21% | -77.47% | -45.98% | 94/157 | 5.02% | 奥赛康 | 35% | 行业排名> |
| 2019-03-31 | 2.24% | -18.25% | -72.62% | 51/157 | 2.45% | 奥赛康 | 28.15% | 行业排名> |
| 2018-12-31 | 8.18% | -4.1% | 18.72% | 62/157 | 7.16% | 宏源药业 | 21.91% | 行业排名> |
| 2018-09-30 | 6.89% | 2.84% | 28.31% | 46/157 | 7.21% | 奥赛康 | 9.7% | 行业排名> |
| 2018-06-30 | 5.37% | 24.02% | 95.99% | 34/157 | 4.63% | 奥赛康 | 40.69% | 行业排名> |
| 2018-03-31 | 2.74% | 29.25% | -67.88% | 34/157 | 2.57% | 信立泰 | 25.93% | 行业排名> |
| 2017-12-31 | 8.53% | -16.13% | 27.31% | 57/157 | 9.62% | 昂利康 | 15.91% | 行业排名> |
| 2017-09-30 | 6.7% | -36.07% | 54.73% | 49/157 | 8.31% | 奥赛康 | 12.08% | 行业排名> |
| 2017-06-30 | 4.33% | -42.57% | 104.25% | 54/157 | 5.56% | 一品红 | 31.62% | 行业排名> |
| 2017-03-31 | 2.12% | -30.26% | -79.15% | 40/157 | 2.1% | 丽珠集团 | 49.43% | 行业排名> |
| 2016-12-31 | 10.17% | 48.47% | -2.96% | 55/157 | 6.05% | 中哲精化 | 54.24% | 行业排名> |
| 2016-09-30 | 10.48% | 84.18% | 38.99% | 22/157 | 5.64% | 华东医药 | 7.2% | 行业排名> |
| 2016-06-30 | 7.54% | 81.25% | 148.03% | 24/157 | 3.52% | ST南新 | 81.7% | 行业排名> |
| 2016-03-31 | 3.04% | 57.51% | -55.62% | 27/157 | 2.69% | 德展健康 | 29.5% | 行业排名> |